Latest News and Events
Filter by
Selections
December 23, 2025
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
Read MoreDecember 15, 2025
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreDecember 8, 2025
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Read MoreDecember 2, 2025
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Read MoreDecember 1, 2025
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
Read MoreNovember 24, 2025
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
Read MoreNovember 18, 2025